Zafgen Thinks Phase III Data Could Be Key To Lifting FDA Hold
This article was originally published in The Pink Sheet Daily
With Phase III data showing beloranib can result in weight loss and improvement in hyperphagia-related behavior, Zafgen hopes the candidate placed on clinical hold Dec. 2 can move back into active development.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.